MelanA polyclonal, anti-human

Background:
Melanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules, they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients.

Alternative Name:
MLANA, Antigen LB39 AA, Antigen LB39-AA, Antigen SK29 AA, Antigen SK29-AA, MAR1, MART 1, MART-1, MART1, Melan A, Melan A protein, Melanoma antigen recognized by T cells 1, Melanoma antigen recognized by T-cells 1, MLAN A, MLANA, OTTHUMP00000021036, OTTHUMP00000021037, OTTHUMP00000021038, Protein Melan-A,

Application Dilution:
WB:1:1,000-1:2,000
FC:1:50-1:100
IHC:1:50-1:200

Specificity: MelanA polyclonal antibody detects endogenous levels of MelanA protein.

Immunogen:
recombinant protein

MW: 20 kDa

Swiss-Prot: Q16655(Human)

Purification & Purity:
ProA affinity purified

Format:
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Storage:
Store at +4°C after thawing. Aliquot store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

For research use only, not for use in diagnostic procedure.